The global solid tumor therapeutics market is expected to grow at a CAGR of 5.5% from 2021 to 2030. The growth of the market is attributed to the increasing incidence of cancer, rising awareness about cancer and its treatment, and technological advancements in the field of oncology. Chemotherapy drugs are used for treating various types of cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer and cervical cancer. Chemotherapy drugs are administered intravenously or orally depending on the type and severity of the disease. Hormone therapy drugs are used for treating breast cancers that have estrogen receptors or progesterone receptors. Immunotherapy drugs are used for treating various types of cancers such as lung cancers that have EGFR mutations or HER2-positive breast cancers. Targeted therapy drugs are used for treating various types of cancers such as colorectal carcinoma with KRAS mutation or pancreatic adenocarcinoma with KIT mutation. -The global cancer drug market is expected to grow at a CAGR of 8.2% from 2016 to 2020, reaching $150 billion by 2020. -Cancer drugs are the fastest growing segment in the pharmaceutical industry and are forecasted to reach $150 billion by 2020. -Cancer drugs are the fastest growing segment in the pharmaceutical industry and are forecasted to reach $150 billion by 2020. -Innovative new treatments for cancer have been developed that can be used as an alternative or in conjunction with chemotherapy, radiation therapy, surgery or other treatments such as immunotherapy and targeted therapies which have shown promising results for patients with advanced cancers who have not responded well enough to other treatments.
Industry Growth Insights published a new data on “Solid Tumor Therapeutics Market”. The research report is titled “Solid Tumor Therapeutics Market research by Types (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy), By Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), By Players/Companies Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Solid Tumor Therapeutics Market Research Report
By Type
Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy
By Application
Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others
By Companies
Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Solid Tumor Therapeutics Market Report Segments:
The global Solid Tumor Therapeutics market is segmented on the basis of:
Types
Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hoffmann-La Roche
- Johnson & Johnson
- Novartis
- AstraZeneca
- Biogen Idec
- Boehringer Ingelheim
- GlaxoSmithKline
- Eli Lilly
- Kyowa Hakko Kirin
- Abbott Laboratories
- Baxter International
Highlights of The Solid Tumor Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Hormone Therapy
- Immunotherapy
- Targeted Therapy
- By Application:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Solid Tumor Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Solid tumor therapies are treatments that aim to kill cancer cells by attacking their solid form. This contrasts with traditional chemotherapy, which attacks the cancerous cells in liquid form.
Some of the key players operating in the solid tumor therapeutics market are Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International.
The solid tumor therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Solid Tumor Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Solid Tumor Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Solid Tumor Therapeutics Market - Supply Chain
4.5. Global Solid Tumor Therapeutics Market Forecast
4.5.1. Solid Tumor Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Solid Tumor Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Solid Tumor Therapeutics Market Absolute $ Opportunity
5. Global Solid Tumor Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Type
5.3.1. Chemotherapy
5.3.2. Hormone Therapy
5.3.3. Immunotherapy
5.3.4. Targeted Therapy
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Solid Tumor Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Lung Cancer
6.3.3. Colorectal Cancer
6.3.4. Prostate Cancer
6.3.5. Cervical Cancer
6.3.6. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Solid Tumor Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Solid Tumor Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Solid Tumor Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Solid Tumor Therapeutics Demand Share Forecast, 2019-2029
9. North America Solid Tumor Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Solid Tumor Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Solid Tumor Therapeutics Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Lung Cancer
9.4.3. Colorectal Cancer
9.4.4. Prostate Cancer
9.4.5. Cervical Cancer
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Solid Tumor Therapeutics Market Size and Volume Forecast by Type
9.7.1. Chemotherapy
9.7.2. Hormone Therapy
9.7.3. Immunotherapy
9.7.4. Targeted Therapy
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Solid Tumor Therapeutics Demand Share Forecast, 2019-2029
10. Latin America Solid Tumor Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Solid Tumor Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Solid Tumor Therapeutics Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Lung Cancer
10.4.3. Colorectal Cancer
10.4.4. Prostate Cancer
10.4.5. Cervical Cancer
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Solid Tumor Therapeutics Market Size and Volume Forecast by Type
10.7.1. Chemotherapy
10.7.2. Hormone Therapy
10.7.3. Immunotherapy
10.7.4. Targeted Therapy
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Solid Tumor Therapeutics Demand Share Forecast, 2019-2029
11. Europe Solid Tumor Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Solid Tumor Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Solid Tumor Therapeutics Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Lung Cancer
11.4.3. Colorectal Cancer
11.4.4. Prostate Cancer
11.4.5. Cervical Cancer
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Solid Tumor Therapeutics Market Size and Volume Forecast by Type
11.7.1. Chemotherapy
11.7.2. Hormone Therapy
11.7.3. Immunotherapy
11.7.4. Targeted Therapy
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Solid Tumor Therapeutics Demand Share, 2019-2029
12. Asia Pacific Solid Tumor Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Solid Tumor Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Solid Tumor Therapeutics Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Lung Cancer
12.4.3. Colorectal Cancer
12.4.4. Prostate Cancer
12.4.5. Cervical Cancer
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Solid Tumor Therapeutics Market Size and Volume Forecast by Type
12.7.1. Chemotherapy
12.7.2. Hormone Therapy
12.7.3. Immunotherapy
12.7.4. Targeted Therapy
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Solid Tumor Therapeutics Demand Share, 2019-2029
13. Middle East & Africa Solid Tumor Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Solid Tumor Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Solid Tumor Therapeutics Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Lung Cancer
13.4.3. Colorectal Cancer
13.4.4. Prostate Cancer
13.4.5. Cervical Cancer
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Solid Tumor Therapeutics Market Size and Volume Forecast by Type
13.7.1. Chemotherapy
13.7.2. Hormone Therapy
13.7.3. Immunotherapy
13.7.4. Targeted Therapy
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Solid Tumor Therapeutics Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Solid Tumor Therapeutics Market: Market Share Analysis
14.2. Solid Tumor Therapeutics Distributors and Customers
14.3. Solid Tumor Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Hoffmann-La Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Johnson & Johnson
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biogen Idec
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer Ingelheim
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlaxoSmithKline
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Kyowa Hakko Kirin
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Abbott Laboratories
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Baxter International
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook